Advertisement

Advertisement
Prostate Cancer

Acute Toxicity With Intensity-Modulated Fractionated Radiotherapy vs Stereotactic Body Radiotherapy for Prostate Cancer

In an analysis from the phase III PACE-B trial reported in The Lancet Oncology, Brand et al found that shortened treatment courses with stereotactic body radiotherapy did not increase gastrointestinal or genitourinary acute toxicity vs intensity-modulated fractionated radiotherapy in low-risk to intermediate-risk localized prostate cancer.

Breast Cancer

ASCO Breakthrough: Breast Cancer Gene Expression Signature May Help Predict Recurrence Postradiotherapy

Researchers have identified a gene pattern that may help predict which patients with breast cancer will have early or late disease recurrence following radiation therapy. The ability to predict the timing of recurrence could change—and improve—treatment strategies and determine the length of follow-up needed. These findings were presented by Speers et al at ASCO Breakthrough: A Global Summit for Oncology Innovators.

Lung Cancer
Immunotherapy

Lung Cancer Research Highlights From ESMO 2019

This week on The ASCO Post Podcast, we’ll be discussing research highlights in lung cancer presented at the ESMO Congress 2019, including the FLAURA trial...


Advertisement
Supportive Care

Community Health Workers May Improve Value of End-of-Life Cancer Care

The results of simple interventions involving community health workers suggest that improvements in value-based cancer care need not come from health-care professionals. According to data presented at the 2019 ASCO Quality Care Symposium, reliance upon community health workers trained to assess patient symptoms and make referrals led to significant differences in health-care utilization, including decreased visits to the emergency department in the last month of life and increased use of hospice for the intervention group. Authors of the study also reported significant reductions in total costs of care among patients receiving the intervention, as compared with the control.

Solid Tumors

Plasma miR371 Expression as a Biomarker for Active Germ Cell Malignancy

In a study reported in the Journal of Clinical Oncology, Nappi et al showed that plasma microRNA miR371 expression was associated with high specificity and positive predictive values in predicting active germ cell malignancy.

Advertisement




More Top Stories

Breast Cancer
Immunotherapy

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: KEYNOTE-522 Trial of Pembrolizumab Plus Chemotherapy

Colorectal Cancer
Immunotherapy

ESMO 2019: Interim Analysis of the BEACON CRC Trial

In an interim analysis of the phase III BEACON CRC trial reported at the European Society for Medical Oncology (ESMO) Congress 2019 (Abstract LBA32) and in The New England Journal of Medicine, Scott Kopetz, MD, PhD, and colleagues found improved overall survival and overall response rate in...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Prostate Cancer

Andrew Kneebone, MD, on an ANZUP Trial on Adjuvant vs Early Salvage Radiotherapy After Prostatectomy

Hematologic Malignancies
Issues in Oncology

High Blood Pressure and Cardiac Adverse Events in Patients Treated With Ibrutinib

Over half of patients treated with the Bruton’s tyrosine kinase inhibitor ibrutinib developed new or worsened high blood pressure within 6 months of starting the medication, according to a study published by Dickerson et al in Blood. The analysis is also the first to tie ibrutinib-related...

Issues in Oncology
Lymphoma

Effect of Race and Ethnicity on Survival in Pediatric and Adolescent Hodgkin Lymphoma

In a Children’s Oncology Group (COG) study reported in the Journal of Clinical Oncology, Kahn et al found that event-free survival in pediatric and adolescent patients with Hodgkin lymphoma was similar by race and ethnicity in COG trials, but that adjusted overall survival was better in white...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Skin Cancer
Immunotherapy

Paolo A. Ascierto, MD, on Melanoma: Results From CheckMate 238 on Adjuvant Nivolumab vs Ipilimumab

Hepatobiliary Cancer

Addition of Doxorubicin to Sorafenib in Advanced Hepatocellular Carcinoma

As reported in JAMA Oncology by Ghassan K. Abou-Alfa, MD, and colleagues, the phase III Alliance/CALGB 80802 trial has shown no progression-free or overall survival benefit with the addition of doxorubicin to sorafenib in patients with advanced hepatocellular carcinoma. The study was stopped early...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...